Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, January 27, 2015
Technology Networks
 
Register | Sign in
Home Page
  News
Return

Paragon Bioservices Acquires Systems for Use in Vaccine and Protein Manufacturing

Published: Wednesday, January 30, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
Company accelerates the development and manufacturing of cell-based VLP-type vaccines using the MaxCyte Flow Electroporation Technology Platform.


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here


Scientific News
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
New Approach May Lead to Inhalable Vaccines
The approach using nanoparticles could lead to development of inhalable vaccines for influenza, pneumonia and tuberculosis.
New Mouse Study Method Enables Comparative Vaccine Studies for Tularemia
The study appears online in Clinical Vaccine and Immunology.
Oxford Vaccine Group Begins First Trial of New Ebola Vaccine
Oxford University doctors and scientists are starting the first safety trial of an experimental preventative Ebola vaccine regimen being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen).
UMMS Receives $6.1 M to Develop Model for Predicting Gene Expression
Insight into regulation of the genes that allow the immune system to recognize pathogens will help scientists rationally design new vaccines and prevent autoimmunity.
GRP78 Protein Possible Universal Therapeutic Target
Drug combination including Viagra is effective tool in targeting the protein.
Adapting Influenza for Vaccine Mass Production
The ability to grow influenza in cell culture rather than chicken eggs paves the way for mass production of the vaccine.
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Closing in on ‘Holy Grail’ of HIV Vaccine
Researchers describe a way to induce long-sought broadly neutralizing antibodies.
Parkinson's Vaccine: EU-Team Launches Clinical Trial
Vaccine candidate based on proprietary technology by AFFiRiS AG.
Scroll Up
Scroll Down
Skyscraper Banner
SELECTBIO Market Reports
LabTube - Videos for the Scientific Community
eposters - The Online Journal of Scientific Posters
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn